Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard C Becker

Showing results (361-370 of 436) with videos related to

Pageof 44
Sort By:
American Heart Journal|June 4, 2018
Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysisBenjamin M Scirica, Sameer Bansilal, Farideh Davoudi, et al.
Clinical Cardiology|February 2, 2018
Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trialAjar Kochar, Anne S Hellkamp, Yuliya Lokhnygina, et al.
International Journal of Cardiology|November 18, 2008
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trialKenneth W Mahaffey, Simon T Tonev, Sarah A Spinler, et al.
Circulation|June 5, 2014
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jonathan L Halperin, Graeme J Hankey, Daniel M Wojdyla, et al.
Journal of the American Heart Association|September 27, 2021
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF TrialAnthony P Carnicelli, Anne S Hellkamp, Kenneth W Mahaffey, et al.
Journal of the American Heart Association|March 26, 2013
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trialDaniel E Singer, Anne S Hellkamp, Jonathan P Piccini, et al.
Circulation|October 31, 2013
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trialLars Wallentin, Daniel Lindholm, Agneta Siegbahn, et al.
Thrombosis Research|April 24, 2017
Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trialYihong Sun, Dayi Hu, Susanna Stevens, et al.
Hypertension (Dallas, Tex. : 1979)|May 10, 2021
Pediatric and Adult Ambulatory Blood Pressure Thresholds and Blood Pressure Load as Predictors of Left Ventricular Hypertrophy in AdolescentsGilad Hamdani, Mark M Mitsnefes, Joseph T Flynn, et al.
Cardiology and Therapy|August 4, 2019
Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AFLeo Ungar, Fatima Rodriguez, Anne S Hellkamp, et al.
Pageof 44

Showing results (361-370 of 436) with videos related to

Sort By:
Pageof 44
American Heart Journal|June 4, 2018
Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysisBenjamin M Scirica, Sameer Bansilal, Farideh Davoudi, et al.
Clinical Cardiology|February 2, 2018
Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trialAjar Kochar, Anne S Hellkamp, Yuliya Lokhnygina, et al.
International Journal of Cardiology|November 18, 2008
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trialKenneth W Mahaffey, Simon T Tonev, Sarah A Spinler, et al.
Circulation|June 5, 2014
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Jonathan L Halperin, Graeme J Hankey, Daniel M Wojdyla, et al.
Journal of the American Heart Association|September 27, 2021
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF TrialAnthony P Carnicelli, Anne S Hellkamp, Kenneth W Mahaffey, et al.
Journal of the American Heart Association|March 26, 2013
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trialDaniel E Singer, Anne S Hellkamp, Jonathan P Piccini, et al.
Circulation|October 31, 2013
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trialLars Wallentin, Daniel Lindholm, Agneta Siegbahn, et al.
Thrombosis Research|April 24, 2017
Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trialYihong Sun, Dayi Hu, Susanna Stevens, et al.
Hypertension (Dallas, Tex. : 1979)|May 10, 2021
Pediatric and Adult Ambulatory Blood Pressure Thresholds and Blood Pressure Load as Predictors of Left Ventricular Hypertrophy in AdolescentsGilad Hamdani, Mark M Mitsnefes, Joseph T Flynn, et al.
Cardiology and Therapy|August 4, 2019
Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AFLeo Ungar, Fatima Rodriguez, Anne S Hellkamp, et al.
Pageof 44